MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Becton Dickinson and Co

Closed

SectorHealthcare

221.9 -2.05

Overview

Share price change

24h

Current

Min

220.16

Max

226.32

Key metrics

By Trading Economics

Income

-118M

303M

Sales

-272M

5.2B

P/E

Sector Avg

38.627

63.778

EPS

3.43

Dividend yield

1.74

Profit margin

5.863

Employees

70,000

EBITDA

-1.3B

453M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+20.96% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.74%

2.39%

Next Earnings

1 May 2025

Market Stats

By TradingEconomics

Market Cap

-6.1B

66B

Previous open

223.95

Previous close

221.9

News Sentiment

By Acuity

31%

69%

84 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Becton Dickinson and Co Chart

Past performance is not a reliable indicator of future results.

Related News

5 Feb 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7 Nov 2024, 12:59 UTC

Earnings

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7 Nov 2024, 12:56 UTC

Earnings

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1 Aug 2024, 11:08 UTC

Earnings

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

3 Jun 2024, 11:18 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

5 Feb 2025, 21:56 UTC

Earnings

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5 Feb 2025, 21:54 UTC

Earnings

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5 Feb 2025, 21:54 UTC

Earnings

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5 Feb 2025, 21:53 UTC

Earnings

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5 Feb 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5 Feb 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q Rev $5.2B >BDX

5 Feb 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q Net $303M >BDX

5 Feb 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q EPS $1.04 >BDX

7 Nov 2024, 11:36 UTC

Earnings

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7 Nov 2024, 11:35 UTC

Earnings

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7 Nov 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q EPS $1.45 >BDX

7 Nov 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7 Nov 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q Rev $5.4B >BDX

7 Nov 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

1 Aug 2024, 10:37 UTC

Earnings

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

1 Aug 2024, 10:35 UTC

Earnings

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

1 Aug 2024, 10:35 UTC

Earnings

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

1 Aug 2024, 10:30 UTC

Earnings

Becton Dickinson 3Q EPS $1.68 >BDX

1 Aug 2024, 10:30 UTC

Earnings

Becton Dickinson 3Q Net $487M >BDX

1 Aug 2024, 10:30 UTC

Earnings

Becton Dickinson 3Q Adj EPS $3.50 >BDX

1 Aug 2024, 10:30 UTC

Earnings

Becton Dickinson 3Q Rev $5B >BDX

4 Jun 2024, 17:26 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3 Jun 2024, 15:30 UTC

Hot Stocks

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3 Jun 2024, 13:26 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3 Jun 2024, 12:25 UTC

Top News
Acquisitions, Mergers, Takeovers

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

Peer Comparison

Price change

Becton Dickinson and Co Forecast

Price Target

By TipRanks

20.96% upside

12 Months Forecast

Average 273.88 USD  20.96%

High 280 USD

Low 260 USD

Based on 9 Wall Street analysts offering 12 month price targets forBecton Dickinson and Co - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

225.12 / 227.935Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

84 / 386 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.